Sun Pharma Advanced Research Company (SPARC) announced leadership changes. Dr. Rajamannar Thennati will retire, and Anil Raghavan will take over as Managing Director and CEO from August 11, 2026, subject to shareholder approval.

SPARC Announces Leadership Transition: Anil Raghavan to be New MD & CEO

Sun Pharma Advanced Research Company (SPARC) has announced a significant change in its top management. Dr. Rajamannar Thennati will retire from the Board of Directors upon completion of his term at the company's 21st Annual General Meeting on August 10, 2026.

Effective August 11, 2026, Mr. Anil Raghavan has been appointed as the new Managing Director and Chief Executive Officer. Mr. Raghavan, who currently serves as the CEO of SPARC, will assume these expanded responsibilities, pending approval from the company's members at the upcoming AGM.

What just happened

SPARC's current CEO, Anil Raghavan, will also become the Managing Director. Dr. Rajamannar Thennati retires after his term ends.

Why this matters

This move consolidates leadership, potentially ensuring strategic continuity under Raghavan's expanded role.

The backstory

Mr. Anil Raghavan brings a diverse background in business strategy, consulting, and technology from his tenures at Arthur Andersen, KPMG, and Quintiles. He also mentors AIRAMATRIX Private Limited, focusing on AI in drug development, aligning with SPARC's R&D focus.

What changes now

Raghavan's dual role as MD and CEO consolidates executive power, aiming for smoother execution of SPARC's innovation-driven strategy.

Risks to watch

Investor approval at the upcoming AGM is a key regulatory hurdle for the appointment.

Peer comparison

(No peer comparison data available in the filing)

Context metrics (time-bound)

Dr. Thennati's retirement date: August 10, 2026.
Mr. Raghavan's appointment effective date: August 11, 2026.

What to track next

Monitor the outcome of the 21st Annual General Meeting for formal shareholder approval of Mr. Raghavan's appointment.